Investors & Media

Sep 27, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Sep 27, 2022 / Sep 27, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

9/6/22

BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
LAVAL, Quebec --(BUSINESS WIRE)--Sep. 6, 2022-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications,...
Read More
8/22/22

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
LAVAL, Quebec --(BUSINESS WIRE)--Aug. 22, 2022-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications,...
Read More
8/10/22

BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
- Completed positive End-of-Phase 2 meeting with the Food and Drug Administration (“FDA”) and received scientific advice from the European Medicines Agency (“EMA”) to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 - - Ended second quarter 2022 with...
Read More